PCVX Stock Forecast 2025-2026
Distance to PCVX Price Targets
PCVX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Vaxcyte (PCVX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PCVX and similar high-potential opportunities.
Latest PCVX Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, PCVX has a bullish consensus with a median price target of $141.50 (ranging from $65.00 to $163.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $34.51, the median forecast implies a 310.0% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Salim Syed at Mizuho, projecting a 372.3% upside. Conversely, the most conservative target is provided by Seamus Fernandez at Guggenheim, suggesting a 88.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PCVX Analyst Ratings
PCVX Price Target Range
Latest PCVX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PCVX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Initiates | $0.00 |
| Apr 8, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $90.00 |
| Apr 1, 2025 | B of A Securities | Jason Gerberry | Buy | Maintains | $137.00 |
| Apr 1, 2025 | Needham | Joseph Stringer | Buy | Maintains | $90.00 |
| Apr 1, 2025 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $100.00 |
| Mar 12, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $160.00 |
| Feb 26, 2025 | Guggenheim | Seamus Fernandez | Buy | Reiterates | $160.00 |
| Feb 26, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $140.00 |
| Feb 24, 2025 | BTIG | Buy | Reiterates | $0.00 | |
| Feb 11, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $14.00 |
| Dec 24, 2024 | BTIG | Buy | Reiterates | $0.00 | |
| Dec 20, 2024 | Goldman Sachs | Chris Shibutani | Buy | Initiates | $135.00 |
| Nov 6, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Nov 6, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $140.00 |
| Sep 10, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $163.00 |
| Sep 4, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $140.00 |
| Sep 3, 2024 | Jefferies | Roger Song | Buy | Maintains | $129.00 |
| Sep 3, 2024 | BTIG | Thomas Shrader | Buy | Maintains | $160.00 |
| Sep 3, 2024 | Needham | Joseph Stringer | Buy | Maintains | $140.00 |
| Sep 3, 2024 | Leerink Partners | David Risinger | Outperform | Maintains | $153.00 |
Vaxcyte Inc. (PCVX) Competitors
The following stocks are similar to Vaxcyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vaxcyte Inc. (PCVX) Financial Data
Vaxcyte Inc. has a market capitalization of $4.27B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -20.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Vaxcyte Inc. (PCVX) Business Model
About Vaxcyte Inc.
Develops innovative vaccines for infectious diseases.
Vaxcyte Inc. generates revenue by developing and commercializing vaccines using its proprietary cell-free protein synthesis platform. This technology enhances vaccine design and production efficiency, allowing the company to target diseases with high unmet medical needs, thereby creating a valuable portfolio of vaccine candidates.
By focusing on improving vaccine efficacy and safety, Vaxcyte plays a crucial role in public health and preventative healthcare measures. Its innovations have the potential to redefine standards in the biotechnology market, offering significant advancements in the fight against vaccine-preventable diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
414
CEO
Mr. Grant E. Pickering M.B.A.
Country
United States
IPO Year
2020
Website
vaxcyte.comVaxcyte Inc. (PCVX) Latest News & Analysis
Latest News
PCVX shares declined following mixed results from a mid-stage study of its pneumococcal vaccine in infants.
Mixed results from PCVX's vaccine study may signal uncertainty around its product's efficacy, impacting stock performance and investor confidence in future revenue potential.
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
25 days agoVaxcyte, Inc. will host a conference call on March 31, 2025, to present topline results from its Phase 2 study of the VAX-24 vaccine for preventing invasive pneumococcal disease in infants.
The upcoming presentation of Vaxcyte's Phase 2 study results for its 24-valent vaccine could significantly impact its stock price and investor confidence, depending on the data's implications for market competitiveness.
Vaxcyte Inc. (PCVX) announced topline results from its Phase 2 study of VAX-24, a 24-valent pneumococcal vaccine, compared to Pfizer's Prevnar 20 in healthy infants.
Vaxcyte's Phase 2 results on VAX-24 could impact competitive positioning in the vaccine market, influencing investor sentiment and stock performance for both Vaxcyte and Pfizer.
Vaccine stocks fall following FDA resignation
24 days agoDr. Kavita Patel discusses the effects of FDA and HHS changes on vaccines and public health policy on 'Fast Money,' highlighting potential implications for investors in health sectors.
Changes in FDA and HHS policies can significantly affect vaccine developments and public health initiatives, impacting healthcare stocks and investor sentiment in related sectors.
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
25 days agoVAX-24 showed a favorable safety profile and strong immune responses in trials, leading to its selection for Phase 3 studies. The company also announced VAX-XL, a new PCV candidate.
VAX-24 shows strong safety and immune response, enhancing its potential as a leading infant vaccine. Positive results may boost the company's stock and market position in pediatric vaccines.
Biotech stocks, including Moderna, Vaxcyte, and Novavax, declined after FDA official Peter Marks resigned following a dispute with Robert F. Kennedy Jr.
The resignation of a key FDA official raises concerns about regulatory stability, impacting investor confidence in biotech stocks like Moderna, Vaxcyte, and Novavax.
Frequently Asked Questions About PCVX Stock
What is Vaxcyte Inc.'s (PCVX) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Vaxcyte Inc. (PCVX) has a median price target of $141.50. The highest price target is $163.00 and the lowest is $65.00.
Is PCVX stock a good investment in 2025?
According to current analyst ratings, PCVX has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PCVX stock?
Wall Street analysts predict PCVX stock could reach $141.50 in the next 12 months. This represents a 310.0% increase from the current price of $34.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vaxcyte Inc.'s business model?
Vaxcyte Inc. generates revenue by developing and commercializing vaccines using its proprietary cell-free protein synthesis platform. This technology enhances vaccine design and production efficiency, allowing the company to target diseases with high unmet medical needs, thereby creating a valuable portfolio of vaccine candidates.
What is the highest forecasted price for PCVX Vaxcyte Inc.?
The highest price target for PCVX is $163.00 from Salim Syed at Mizuho, which represents a 372.3% increase from the current price of $34.51.
What is the lowest forecasted price for PCVX Vaxcyte Inc.?
The lowest price target for PCVX is $65.00 from Seamus Fernandez at Guggenheim, which represents a 88.4% increase from the current price of $34.51.
What is the overall PCVX consensus from analysts for Vaxcyte Inc.?
The overall analyst consensus for PCVX is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $141.50.
How accurate are PCVX stock price projections?
Stock price projections, including those for Vaxcyte Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.